Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AdageneADAG -4.06%58 EV-to-OCF is -5.22 as of Sep. 09, 2026. GuruFocus rates ADAG with a GF Score™ of 58/100 and a GF Value™ of $14.65 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,404 Biotechnology companies, Adagene ranks better than 58.4% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Adagene's Enterprise Value is $100.43 Mil.
Adagene's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-19.25 Mil. Therefore, Adagene's EV-to-OCF for today is -5.22.
The historical rank and industry rank for Adagene's EV-to-OCF or its related term are showing as below:
ADAG'
s EV-to-OCF Range Over the Past 10 Years
Min: -38.54 Med: -0.7 Max: 2.96
Current: -5.22
During the past 8 years, the highest EV-to-OCF of Adagene was 2.96. The lowest was -38.54. And the median was -0.70.
ADAG's EV-to-OCF is ranked better than 58.4% of 1404
companies
in the Biotechnology industry
Industry Median: -3.65
vs ADAG: -5.22
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Adagene's share price for today is $3.31.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adagene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.376.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Adagene EV-to-OCF Related Terms
Adagene EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Adagene's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adagene's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adagene EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adagene's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Adagene's EV-to-OCF falls into.
Adagene's current Enterprise Value is $100.43 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adagene's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-19.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adagene (ADAG) has a EV-to-OCF of -5.22 as of Sep. 09, 2026. According to the industry distribution chart, Adagene ranks #584 out of 1404 companies in the Biotechnology industry, placing it in the top 41.6%.
Is Adagene's EV-to-OCF too high?
Adagene's current EV-to-OCF is -5.22. Based on the distribution chart, Adagene ranks #584 out of 1404 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Adagene has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adagene's EV-to-OCF compare to NGEN and NMRA?
According to the Biotechnology industry distribution chart, Adagene ranks #584 out of 1404 companies for EV-to-OCF. This puts Adagene in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Adagene's current EV-to-OCF is -5.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Based on GuruFocus' analysis, Adagene (ADAG) is currently considered Possible Value Trap. The stock's GF Value™ is $14.65, compared to a current price of $3.31 — trading 77.4% below its estimated fair value. The current EV-to-OCF is -5.22. Adagene's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Adagene (ADAG), the current EV-to-OCF is -5.22 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adagene (ADAG) Overvalued in 2026?
Based on GuruFocus' analysis, Adagene stock appears to be undervalued.
The current stock price of $3.31 is trading 77.4% below its estimated GF Value™ of $14.65.
GuruFocus considers Adagene to be Possible Value Trap.
Key valuation signals for ADAG:
EV-to-OCF: -5.22
GF Value™: $14.65 vs. price of $3.31 (77.4% below fair value)
No single metric tells the full story. See the ADAG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
58GF Score
Get the complete analysis for ADAG
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADAG has been successfully added to your 
